Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs
thalidomide and lenalidomide has substantially improved outcomes for patients with multiple …

In multiple myeloma (MM), the impact of complete response (CR) could be shown only after
introduction of high-dose therapy plus autologous stem cell transplantation (ASCT). In the …

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These
neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone …

Purpose The purpose of this study was to confirm overall survival (OS) and other clinical
benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan and …

В руководстве с современных позиций освещены вопросы этиологии, патогенеза,
классификации, диагностики и лечения множественной миеломы. В основу работы …

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma
with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib …

The goal of treatment for multiple myeloma (MM) is to improve patients' long-term outcomes.
One important factor that has been associated with prolonged progression-free and overall …

Bortezomib (VELCADE®) is a proteasome inhibitor that not only targets the myeloma cell,
but also acts in the bone marrow micro-environment, inhibiting the binding of myeloma cells …

Multiple myeloma (MM) is a neoplastic plasma cell disorder that results in end-organ
damage (hypercalcemia, renal insufficiency, anemia, or skeletal lesions). Patients should …

Autologous stem cell transplantation (ASCT) is recommended for younger patients with
newly diagnosed multiple myeloma. Achieving complete response (CR) or at least very …